Ftse Mib
35.421,49
0,30%
DAX
20.392,42
0,36%
S&P 500
5.918,25
0,00%
NASDAQ
19.478,88
0,00%
Bitcoin
94.890,42
2,68%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni Germania TG Genmab AS (GE9) Genmab AS (GE9) Notizie

Genmab AS

GE9
214,00
-1,30 (-0,60%)
12:50:29 - Dati in Tempo Reale
Borsa: Tradegate
Tipo: Azione Ordinaria
Valuta: EUR

Ultime notizie

Data Ora Fonte Titolo
03/1/202519:55UKREGGenmab to Present at the 43rd Annual J.P. Morgan Healthcare..
11/12/202414:20UKREGGenmab to Hold 2024 R&D Update and ASH Data Review Meeting
09/12/202418:00UKREGTwo Data Analyses from Clinical Trials Show Epcoritamab..
08/12/202417:00UKREGInvestigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy..
08/12/202401:12UKREGInvestigational Epcoritamab (DuoBody® CD3xCD20) Combination..
03/12/202422:35UKREGCapital Increase in Genmab as a Result of Employee Warrant..
03/12/202413:07UKREGTransactions With Shares and Linked Securities in Genmab A/S..
25/11/202417:05UKREGGenmab to Present at Citi’s Global Healthcare Conference
21/11/202420:47UKREGGrant of Restricted Stock Units and Warrants to Employees in..
06/11/202417:01UKREGGenmab Announces Financial Results for the First Nine Months..
05/11/202419:10UKREGGenmab to Present at Jefferies London Healthcare Conference
05/11/202418:00UKREGGenmab to Showcase Strength and Breadth of Comprehensive..
15/10/202412:25UKREGGenmab Announces Net Sales of DARZALEX® (daratumumab) for..
04/10/202419:55UKREGMajor Shareholder Announcement
26/9/202421:17UKREGGrant of Restricted Stock Units and Warrants to Employees in..
15/9/202414:45UKREGInvestigational Rinatabart Sesutecan (Rina-S) Shows..
10/9/202422:06UKREGCapital Increase in Genmab as a Result of Employee Warrant..
26/8/202418:26UKREGGenmab to Present at Morgan Stanley 22nd Annual Global..
19/8/202420:00UKREGTEPKINLY® (epcoritamab) Receives Second European Commission..
16/8/202415:00UKREGGenmab Announces Changes to its Executive Committee
13/8/202420:53UKREGTransactions with shares and linked securities in Genmab A/S..
13/8/202420:50UKREGCapital Increase in Genmab as a Result of Employee Warrant..
08/8/202417:03UKREGGenmab Announces Financial Results for the First Half of..
08/8/202417:00UKREGGenmab Updates 2024 Financial Guidance
05/8/202411:50UKREGGenmab Takes Full Control of Acasunlimab Development Program
17/7/202412:25UKREGGenmab Announces Net Sales of DARZALEX® (daratumumab) for..
28/6/202408:00GLOBEEpcoritamab (TEPKINLY®) Receives Positive CHMP Opinion for..
27/6/202423:00GLOBECompletion of Share Buy-back Program
27/6/202401:03GLOBEEPKINLY® (epcoritamab-bysp) Approved by U.S. FDA for..
24/6/202415:55GLOBETransactions in Connection with Share Buy-back Program
18/6/202420:45GLOBECapital Increase in Genmab as a Result of Employee Warrant..
17/6/202415:33GLOBETransactions in Connection with Share Buy-back Program
12/6/202421:45GLOBEGrant of Restricted Stock Units and Warrants to Employees in..
11/6/202420:50GLOBETransactions with shares and linked securities in Genmab A/S..
10/6/202416:18GLOBETransactions in Connection with Share Buy-back Program
05/6/202418:51GLOBEGenmab to Participate in a Fireside Chat at the Goldman..
03/6/202415:09GLOBETransactions in Connection with Share Buy-back Program
03/6/202415:00GLOBEInvestigational Tisotumab Vedotin Phase 2 Data Demonstrates..
02/6/202423:30GLOBEPreliminary Analysis of Data Evaluating Investigational..
01/6/202416:00GLOBEInvestigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in..
27/5/202416:16GLOBETransactions in Connection with Share Buy-back Program
23/5/202423:00GLOBEGenmab to Showcase Data in Various Patient Populations to be..
21/5/202417:06GLOBEGenmab Completes Acquisition of ProfoundBio
21/5/202413:19GLOBETransactions in Connection with Share Buy-back Program
14/5/202416:02GLOBEGenmab to Present New and Updated Results From Multiple..
13/5/202416:09GLOBETransactions in Connection with Share Buy-back Program
07/5/202420:27GLOBECapital Increase in Genmab as a Result of Employee Warrant..
06/5/202416:01GLOBETransactions in Connection with Share Buy-back Program
02/5/202417:01GLOBEGenmab Announces Financial Results for the First Quarter of..
30/4/202400:40GLOBETIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval..
Apertura: 214,80 Min: 214,00 Max: 214,80
Chiusura: 215,30

La tua Cronologia

TG
GE9
Genmab AS
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network